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Previous reports have suggested that the rate of de novo cholesterol synthesis in the adult vertebrate retina is extremely slow. We investigated 
cholesterol biosynthesis in the adult rat retina in vivo, following intravitreal injection of [3Hjacetate. HPLC analysis of retinal non-saponifiable 
lipid extracts revealed co-elution of radioactivity with endogenous cholesterol mass within 4.5 h post-injection. Incorporation of [‘HIacetate into 
cholesterol was markedly reduced by co-injection of known inhibitors of the cholesterol pathway. In contrast o previous results with retinas from 
other species, no radiolabel or mass corresponded to squalene, except in lipid extracts from retinas treated with NB-598, a squalene poxidase 
inhibitor. These results demonstrate, for the first time, the capacity of the adult vertebrate retina to rapidly synthesize cholesterol de novo. 
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1. INTRODUCTION 
Although cholesterol is a constituent of vertebrate 
retinas [l], and has been implicated in the modulation 
of photoreceptor function [2], its biogenic origin re- 
mains to be determined. Studies performed in vitro with 
isolated adult bovine [3] and frog [4,5] retinas or retinal 
homogenates [6] in short-term incubations (l-6 h) have 
shown that little, if any, cholesterol is synthesized from 
radiolabeled de novo precursors. Instead, the major ra- 
diolabeled non-saponifiable lipid products is squalene, 
with lesser and variable amounts of sterol intermediates 
(e.g. lanosterol). Similar results have been obtained in 
vivo, l-2 h following intravitreal administration of 
[3H]mevalonate in the bovine eye [7]. In the frog eye, 
conversion of [3H]mevalonate or [3H]acetate to cholest- 
erol (as the major radiolabeled product) takes 2 1 day 
[8]. Unlike bovine retina or rod outer segment mem- 
branes [9], frog retina and rod outer segment mem- 
branes contain significant amounts of squalene mass 
[4,5], in addition to cholesterol. Furthermore, the 
squalene produced from radiolabeled e novo precursors 
in frog retina is incorporated into the rod outer seg- 
ments, where it apparently is not further metabolized [8]. 
We recently described [lo] the production of a 
dysplastic-like retinal degeneration in adult rats follow- 
ing intravitreal injection of lovastatin, a potent inhibitor 
of HMG-CoA reductase (EC 1.1.1.34) [l 11. In addition 
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to blocking cholesterol biosynthesis, this inhibitor also 
affects the synthesis of a variety of other biologically 
significant products, such as isoprenyl pyrophosphates, 
ubiquinones, dolichols, and isoprenylated proteins 
[12,13]. Due to the fact that cholesterol biogenesis is 
thought to be negligible in retina, the involvement of the 
sterol branch of the isoprenoid pathway in the etiology 
of the lovastatin-induced retinal degeneration was dis- 
counted [lo]. However, studies concerning the de novo 
synthesis of cholesterol in the rat retina have not been 
reported, heretofore. Herein, we present the first evi- 
dence for rapid de novo synthesis of cholesterol in the 
rat retina in vivo, as well as the ability of known inhib- 
itors of the cholesterol pathway to block retina isopre- 
noid lipid synthesis, using [3H]acetate as a radiolabeled 
precursor. 
2. MATERIALS AND METHODS 
2.1. Materials 
Unless otherwise specified, all reagents were analytical reagent 
grade and obtained from Sigma. All solvents were HPLC grade and 
obtained from Burdick and Jackson. [‘HIAcetate (Na salt, 27 Gil 
mmol) was from ICN Radiochemicals. [4-‘4C]Cholesterol (40 mCi/ 
mmol) and [1,5,9,14,20,24-‘4C]squalene (50 mCi/mmol) were from Du 
Pont/NEN Research Products and American Radiolabeled Chemi- 
cals, respectively. Non-radioactive standards of cholesterol, lanos- 
terol, and squalene were from Sigma. Lathosterol(5a-cholest-7-en-3/3- 
01) was from Research Plus Steroids; desmosterol (cholesta-5,24-dien- 
3/I-01) was from Steraloids, Inc. The following compounds were ob- 
tained as gifts from the sources pecified: lovastatin (Dr. A.W. Alberts, 
Merck Sharpe & Dohme), NB-598 (Dr. M. Horie, Banyu Pharmaceu- 
tical Co.), and 5a-cholest-8(14)-en-3/7-ol (Dr. R.A. Pascal, Princeton 
University). 
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2.2. Intravitreal injections 
All procedures involving animals conformed to the ARVO Resolu- 
tion on the Use of Animals in Research and the NIH Guide for the Care 
ana’ Use of Laboratory Animals. Adult female Long-Evans pigmented 
rats (2W250 g), maintained for at least 1 week on cyclic lighting (12 
h light, 12 h dark), were anesthetized by intraperitoneal injection with 
a ketamineacetylpromazine mixture. Intravitreal injections were per- 
formed as described previously [lo], using a 32-gauge needle affixed 
to a 25 ~1 Hamilton syringe barrel. Two groups of animals (4 per 
group) were used. In one group, one eye of each animal received 
rqacetate (0.25 mCi, dissolved in 7.5 ~1 of 10 mM Tris-Cl, pH 7.4); 
the contralateral eye received a solution containing the same amount 
of [‘HIacetate, supplemented with lovastatin (100 pug in 7.5 ~1 10 mM 
T&-Cl, pH 7.4), prepared as the Na salt [14]. In the second group, one 
eye of each animal received 0.25 mCi of [‘HIacetate in 5 ~1 of Me,SO, 
while the contralateral eye was injected with 5 ~1 of Me,SO containing 
0.25 mCi of [3H]acetate plus NB-598 (5Opg), an inhibitor of squalene- 
2,3-epoxidase (EC 1.14.99.7) [15]. In this group, Me&SO was used in 
place of Tris-Cl buffer as a vehicle, due to the limited solubility of 
NB-598 in aqueous buffer. After allowing 4.5 h (NB-598 group) or 
6 h (lovastatin group) for precursor uptake and metabolism, the ani- 
mals were sacrificed by intracardiac pentobarbital overdose, enu- 
cleated, and the neural retinas were isolated. 
2.3. Extraction and analysis of retina nonsaponifiable lipids 
Retinas were individually saponified in 1 ml of methanolic KOH 
(60% (w/v) KOH in 80% MeOH, 20% H,O (v/v)) for 1 h at 1OO’C 
under argon in sealed glass tubes. After cooling and addition of 2 ml 
of H,O, the non-saponifiable lipids were extracted with petroleum 
ether (2 x 5 ml each); the combined extracts were washed with 1 ml 
of 5% (v/v) acetic acid, evaporated to dryness under argon, and re- 
dissolved in 0.20 ml of MeOH. An aliquot (20 ~1) of the extract was 
taken for measurement of radioactivity by liquid scintillation count- 
ing. Another aliquot (100 ~1) was taken for analysis by reverse-phase 
HPLC. A Waters/Millipore 600 series HPLC system was employed, 
equipped with either an Ultracarb 3 ODS-20 reverse-phase column 
(4.6 x 150 mm, 3 pm resin; Phenomenex) or a silica column (4.6 x 220 
mm, 5 pm resin; Brownlee Laboratories). For reverse-phase HPLC, 
a mobile phase of 100% MeOH at 1 ml/min was employed, for 
straight-phase (silica) HPLC, the mobile phase was 1% (v/v) reagent 
alcohol in 99% (v/v) hexane, at a flow rate of 1 mYmin. Radioactivity 
was detected with a Radiomatic Flo-One/Beta model CR flow- 
through liquid scintillation detector (0.5 ml flow cell), using Packard 
Flo-Stint III cocktail (41 v/v ratio, relative to mobile phase; ‘H count- 
ing efficiency, 35%; 14C counting efficiency, 95%). Mass was detected 
simultaneously by UV absorbance (210 nm) with a Waters/Millipore 
model 481 spectrophotometer, and quantified (in comparison with a 
series of cholesterol standards) using a Waters/Millipore model 745B 
integrator. The elution positions for mass and radioactivity were cali- 
brated using ?labeled and non-radioactive standards of cholesterol 
and squalene. 
3. RESULTS AND DISCUSSION 
3.1. Effect of lovastatin on rH]acetate incorporation 
into retina non-saponifiable lipids 
Fig. 1 shows representative reverse-phase, radio- 
HPLC profiles obtained for rat retina non-saponifiable 
lipids, 6 h following intravitreal injection of [3H]acetate, 
with (Fig. 1B) or without (Fig. 1A) companion lovas- 
tatin. In both cases, a major UV-absorbing component 
was observed with a retention time of 11.7 min. Under 
the chromatographic onditions employed, an authentic 
standard of cholesterol eluted with a retention time of 
11.7 min, and was well resolved from standards of 
desmosterol (retention time 9.7 min), 5a-cholest-8(14)- 
en-3/3-ol (retention time 10.2 min), and squalene (reten- 
tion time 13.7 min) (see Fig. 1C). Based upon the inte- 
grated UV absorbance values of the ‘cholesterol-like’ 
mass peaks, the cholesterol mass in the control and 
lovastatin-treated samples was comparable (80.4 nmol 
and 86.4 nmol, respectively). 
In the radiochromatogram of the control sample 
(Fig. lA), the major peak of radioactivity (= 65% of 
total recovery) was coincident with the cholesterol-like 
mass peak. In addition, = 18% of the recovered radioac- 
Fig. 1. Reverse-phase radio-HPLC profile of rat retina non-saponifiable lipids, obtained 6 h after intravitreal injection of [‘HIacetate (0.25 mCi/eye) 
in the absence (A) or presence (B) of lovastatin (Na salt, 100 pug). Upper panels (A,B), UV absorbance (210 nm), normalized to give full-scale 
response for cholesterol (arrowheads); lower panels, ‘H radioactivity (total recovered radioactivity: A, 8,170 dpm; B, 790 dpm) normalized to same 
full-scale response. (C) Elution profile of authentic standards of (1) desmosterol, (2) 5a-cholest-8(14)-en-3/3-01, (3) cholesterol, and (4) squalene. 
235 
Volume 335, number 2 FEBS LETTERS December 1993 
Retention Time (minutes) 
Fig. 2. Straight-phase (silica) radio-HPLC elution profiles. (A) UV 
absorbance (210 nm) of authentic standards of (1) lanosterol, (2) 
cholesterol, and (3) lathosterol. (B) “C-labeled standards of squalene 
(S) and cholesterol (full scale, 500 dpm). (C) Cholesterol-like, ‘H- 
labeled material (see Fig. 1A) obtained by reverse-phase HPLC of 
control rat retina non-saponifiable lipids (full scale, 2,500 dpm). 
tivity eluted with a retention time of 9.7 min, consistent 
with the chromatographic behavior of desmosterol or 
a related Cz7 3/I-monohydroxy sterol. In contrast, the 
lovastatin-treated sample (Fig. 1B) exhibited no radio- 
labeled components corresponding to cholesterol or 
known intermediates in the sterol biosynthetic pathway. 
Virtually all of the recovered radioactivity (which corre- 
sponded to I 10% of the control value) consisted of 
very polar material of unknown identity (retention time 
2.2 min); similar radiolabeled material, representing 
x 14% of the recovered radioactivity, was also observed 
in the control sample. These results are consistent with 
the expected inhibition of HMG-CoA reductase by lo- 
vastatin [ 111. Notably, in contrast to results obtained in 
previous studies with vertebrate retinas [3-81, neither 
the control nor the lovastatin-treated sample exhibited 
detectable mass or radioactivity corresponding to 
squalene. 
A portion of the cholesterol-like material from the 
control sample was collected from the reverse-phase 
column (11.1-12.7 min), evaporated to dryness, supple- 
mented with internal standards of 14C-labeled cholest- 
erol (3,200 dpm) and squalene (1,200 dpm), plus non- 
radiolabeled lanosterol (10 pg) and lathosterol (20 pg), 
and then analyzed by straight-phase HPLC. The results 
are shown in Fig. 2. The 3H radioactivity derived bio- 
synthetically from rat retina (Fig. 2C) eluted quantita- 
tively as a homogeneous peak with a retention time of 
10.5 min, which corresponded exactly to the elution 
time of both the internal [14C]cholesterol standard (Fig. 
2B) and the cholesterol mass peak (Fig. 2A). Under the 
chromatographic onditions employed, cholesterol was 
well resolved from squalene (retention time 2.5 min), 
lanosterol (retention time 6.9), and lathosterol (reten- 
tion time 11.5 min). 
3.2. Effect of NB-598 on r3H]acetate incorporation into 
retina non-sapokjiable lipids 
In a separate xperiment, rats were injected intravit- 
really with [3H]acetate, with or without the squalene 
epoxidase inhibitor, NB-598, and the retinas were re- 
moved 4.5 h later. Representative reverse-phase radio- 
HPLC chromatograms of the corresponding non-sap- 
onifiable lipid extracts are shown in Fig. 3. In the course 
of this particular chromatographic analysis, standards 
of cholesterol and squalene exhibited retention times of 
= 14.0 and 15.2 min, respectively (+ 0.1 min). In the 
radiochromatogram of the control sample (Fig. 3A), the 
most prominent peak of radioactivity (= 54% of total 
recovery) was coincident with endogenous mass, having 
the chromatographic properties of cholesterol; again, 
no radiolabel or mass corresponded to squalene. In the 
chromatogram of the sample obtained from an eye that 
was co-injected with [3H]acetate and NB-598 (Fig. 3B), 
not only did the most prominent peak of radioactivity 
correspond to squalene (= 42% of total recovery), but 
there was detectable mass coincident with the squalene 
standard. These results are consistent with the expected 
effects of a squalene poxidase inhibitor [ 151. Some radi- 
oactivity (= 15% of total recovery) was also detected 
coincident with the cholesterol mass peak; however, the 
relative amount of radiolabel corresponding to cholest- 
erol was reduced almost 4-fold, relative to the control. 
Hence, either the conditions were not optimal for com- 
plete squalene poxidase inhibition, or some [3H]acetate 
uptake and conversion to sterols took place prior to 
inhibition by NB-598. In both chromatograms, acluster 
of radiolabeled components was observed with reten- 
tion times in the range of = 10.5-12 min; these peaks 
were markedly reduced in the NB-598-treated sample, 
relative to the control, suggesting that they may corre- 
spond to sterol intermediates in the cholesterol path- 
way. However, these components were not character- 
ized further. 
3.3. Cholesterol synthesis in the vertebrate retina 
Taken together, these results demonstrate that rat 
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Fig. 3. Reverse-phase radio-HPLC profile of rat retina non-saponifiable lipids, obtained 4.5 h after intravitreal injection of [HIacetate (0.25 mCi/eye) 
in the absence (A) or presence (B) of NB-598 (50 ,ug). Upper panels, UV absorbance (210 nm); lower panels, ‘H radioactivity (total recovered 
radioactivity: A, 12,100 dpm; B, 17,280 dpm). Arrows denote elution positions of authentic holesterol (C) and squalene (S) standards, under the 
conditions employed. 
retina is capable of relatively rapid de novo synthesis of 
cholesterol in vivo. In contrast, previous studies with 
other species, most of which were performed with either 
isolated retinas in vitro [3-51 or retinal homogenates [6], 
have shown minimal de novo synthesis of cholesterol, 
with attendant accumulation of squalene and sterol in- 
termediates. It is unlikely that this discrepancy is simply 
a function of in vitro vs. in vivo factors, since such sterol 
precursor accumulation has also been observed in vivo 
in bovine [7] and frog retinas [8]. In frog retina, appre- 
ciable synthesis of cholesterol requires several hours-to- 
days. Considering the obvious merits of the rat as an 
experimental animal for comparative in vivo and in 
vitro studies of retina metabolism [16,17], the rat is 
recommended as the animal of choice for further inves- 
tigations concerning cholesterol synthesis, intracellular 
transport, turnover, and function in the vertebrate ret- 
ina. 
3.4. Lovastatin-induced retinal degeneration 
The selective inhibition of the sterol pathway af- 
forded by NB-598, as opposed to the generalized inhibi- 
tion of isoprenoid metabolism produced with lovas- 
tatin, provides the means to specifically evaluate the 
involvement of cholesterol metabolism in the lovastatin- 
induced retinal degeneration [lo]. Preliminary results in 
our laboratories (unpublished) indicate that intravitreal 
NB-598 does not produce a retinal degeneration, under 
conditions where cholesterol synthesis is inhibited by 
80-100%. Currently, we are pursuing more detailed 
studies of the dose dependence and persistence of the 
inhibitory activity of intravitreal ovastatin and NB-598 
with regard to their histological and functional conse- 
quences on the rat retina. 
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